NKGen Biotech (NKGN) News Today $0.64 +0.07 (+13.25%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period NKGen Biotech Awards Stock Options to ExecutivesDecember 13, 2024 | markets.businessinsider.comNKGen Biotech Secures Key Role in NKMax DealDecember 3, 2024 | markets.businessinsider.comNKGen Biotech Selected as Stalking Horse Bidder for NKMaxDecember 2, 2024 | globenewswire.comNKGen Biotech, Inc.: NKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNovember 29, 2024 | finanznachrichten.deNKGen Biotech gets Nasdaq notice related to delayed quarterly reportNovember 28, 2024 | markets.businessinsider.comNKGen Biotech Receives Notifications From Nasdaq Related to Delayed Quarterly Report and Decision of the Nasdaq Hearings PanelNovember 26, 2024 | globenewswire.comNKGen Flat on Presentation of Alzheimer's TreatmentOctober 30, 2024 | baystreet.caNKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer's Disease at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 29, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)October 15, 2024 | globenewswire.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceOctober 8, 2024 | finance.yahoo.comNKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer's Disease (CTAD) ConferenceOctober 8, 2024 | globenewswire.comNKGen Biotech (NASDAQ:NKGN) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comNKGen Biotech (NASDAQ:NKGN) Stock, Short Interest ReportSeptember 26, 2024 | benzinga.comNKGen Biotech amends agreement, increases share considerationSeptember 14, 2024 | investing.comNKGen Biotech's Positive Phase 1 Clinical Data in Moderate Alzheimer's Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a TrialSeptember 12, 2024 | globenewswire.comNKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comNKGen Biotech Inc. WtAugust 24, 2024 | wsj.comNKGen Biotech Receives Notification From Nasdaq Related to Delayed Quarterly ReportAugust 22, 2024 | globenewswire.comNKGen Biotech, Inc. (NKGNW)August 1, 2024 | finance.yahoo.comNKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International ConferenceJuly 30, 2024 | markets.businessinsider.comNKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer's Association International ConferenceJuly 30, 2024 | globenewswire.comNKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International ConferenceJuly 19, 2024 | finance.yahoo.comWhy NKGen Biotech (NKGN) Stock Is SkyrocketingJuly 19, 2024 | msn.comNKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International ConferenceJuly 18, 2024 | globenewswire.comNKGen Biotech Appoints Dr. Marco Gottardis to its Board of DirectorsJuly 15, 2024 | globenewswire.comNKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 12, 2024 | globenewswire.comNKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 3, 2024 | globenewswire.comNKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | globenewswire.comNKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring TodayMay 20, 2024 | investorplace.comNKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring TodayMay 20, 2024 | investorplace.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | markets.businessinsider.comWhy NKGen Biotech Stock Is Moving Higher MondayMay 20, 2024 | msn.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | finance.yahoo.comNKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's DiseaseMay 20, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & ExhibitionMay 16, 2024 | globenewswire.comNKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease TherapyApril 29, 2024 | marketwatch.comNKGen Biotech: FDA Clears IND Application For SNK01 NK Cell Therapy - Quick FactsApril 29, 2024 | markets.businessinsider.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s DiseaseApril 29, 2024 | finance.yahoo.comNKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson's DiseaseApril 29, 2024 | globenewswire.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 25, 2024 | finance.yahoo.comNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 25, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 24, 2024 | globenewswire.comReplicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual MeetingApril 22, 2024 | finance.yahoo.comWhat's Going On With Nano-Cap NKGen Biotech Stock On Monday?April 22, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development SummitApril 18, 2024 | finance.yahoo.comNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development SummitApril 18, 2024 | globenewswire.comNKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023April 17, 2024 | investorplace.comNKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical ProgramsApril 11, 2024 | globenewswire.comNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global ConferenceMarch 25, 2024 | globenewswire.comNKGen Biotech appoints new chairperson amid leadership shuffleMarch 22, 2024 | investing.com Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. NKGN Media Mentions By Week NKGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKGN News Sentiment▼0.000.60▲Average Medical News Sentiment NKGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKGN Articles This Week▼01▲NKGN Articles Average Week Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies InterCure News Oncolytics Biotech News Cue Biopharma News BeyondSpring News VolitionRx News Atara Biotherapeutics News Connect Biopharma News Spero Therapeutics News Aadi Bioscience News Mural Oncology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NKGN) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
